IL302649A - A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections - Google Patents

A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Info

Publication number
IL302649A
IL302649A IL302649A IL30264923A IL302649A IL 302649 A IL302649 A IL 302649A IL 302649 A IL302649 A IL 302649A IL 30264923 A IL30264923 A IL 30264923A IL 302649 A IL302649 A IL 302649A
Authority
IL
Israel
Prior art keywords
aat
composition
pharmaceutical composition
protein
use according
Prior art date
Application number
IL302649A
Other languages
English (en)
Hebrew (he)
Inventor
Manfred Stangl
Michael Strassmair
Original Assignee
Aatec Medical Gmbh
Manfred Stangl
Michael Strassmair
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20206287.3A external-priority patent/EP3995130A1/en
Application filed by Aatec Medical Gmbh, Manfred Stangl, Michael Strassmair filed Critical Aatec Medical Gmbh
Publication of IL302649A publication Critical patent/IL302649A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL302649A 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections IL302649A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206287.3A EP3995130A1 (en) 2020-11-06 2020-11-06 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP21159620 2021-02-26
PCT/EP2021/080936 WO2022096708A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Publications (1)

Publication Number Publication Date
IL302649A true IL302649A (en) 2023-07-01

Family

ID=78806458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302649A IL302649A (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Country Status (7)

Country Link
US (1) US20230414730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240323A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023547728A (cg-RX-API-DMAC7.html)
AU (1) AU2021375735A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200691A1 (cg-RX-API-DMAC7.html)
IL (1) IL302649A (cg-RX-API-DMAC7.html)
WO (1) WO2022096708A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
CN115381857B (zh) * 2022-10-28 2023-02-03 上海市东方医院(同济大学附属东方医院) 间充质干细胞在制备治疗hpv持续感染的药物中的应用
US20240309329A1 (en) * 2023-03-17 2024-09-19 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025227013A1 (en) * 2024-04-26 2025-10-30 Musc Foundation For Research Development Extracellular vesicles from alpha-1 antitrypsin overexpressing cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
JP4426179B2 (ja) * 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ,インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
WO2009005877A2 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
JP5727458B2 (ja) 2009-04-13 2015-06-03 アプセト ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフトApceth Gmbh & Co. Kg 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法
KR102063069B1 (ko) * 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Also Published As

Publication number Publication date
WO2022096708A1 (en) 2022-05-12
JP2023547728A (ja) 2023-11-13
US20230414730A1 (en) 2023-12-28
AU2021375735A1 (en) 2023-06-08
CA3200691A1 (en) 2022-05-12
EP4240323A1 (en) 2023-09-13
AU2021375735A9 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20230414730A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
Pocsfalvi et al. COVID-19 and extracellular vesicles: an intriguing interplay
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染
WO2019046664A1 (en) COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS
JP2005511644A (ja) 核酸およびカチオン性アミノグリコシドの組成物ならびにそれを使用および調製する方法
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
US20120231088A1 (en) Use of Deuterium Oxide for the Treatment of Virus-Based Diseases of the Respiratory Tract
CN115427076B (zh) 用于治疗冠状病毒感染的人去泛素化酶抑制剂
US20260116934A1 (en) Compositions and Methods for Delivering CFTR Polypeptides
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
JP2023527791A (ja) ウイルス性呼吸器感染症を治療するための方法
KR20220134764A (ko) 염증성 폐 질환의 흡입식 치료를 위한 인간 항염증성 펩타이드
US20260000791A1 (en) In vivo gene therapy using intraosseous delivery of a lentiviral gene construct
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
JP2001503401A (ja) 直接タンパク質送達することが困難な領域での遺伝子送達及び発現
US7012091B1 (en) Inhalable inhibitors of inflammation in the respiratory tract
US20130064792A1 (en) Therapy for influenza like illness
KR20210097756A (ko) 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
JP2023523035A (ja) キニーネ及び先天性免疫応答を生じさせるためのその使用
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
CN118717729A (zh) 一种干扰素协同外泌体雾化吸入制剂及其制备方法和应用